Donanemab in Early Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease. METHODS: ), the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory (ADCS-iADL), and the Mini-Mental State Examination (MMSE), as well as the change in the amyloid and tau burden on PET. RESULTS: A total of 257 patients were enrolled; 131 were assigned to receive donanemab and 126 to receive placebo. The baseline iADRS score was 106 in both groups. The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P = 0.04). The results for most secondary outcomes showed no substantial difference. At 76 weeks, the reductions in the amyloid plaque level and the global tau load were 85.06 centiloids and 0.01 greater, respectively, with donanemab than with placebo. Amyloid-related cerebral edema or effusions (mostly asymptomatic) occurred with donanemab. CONCLUSIONS: In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. Longer and larger trials are necessary to study the efficacy and safety of donanemab in Alzheimer's disease. (Funded by Eli Lilly; TRAILBLAZER-ALZ ClinicalTrials.gov number, NCT03367403.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The phase 3 trial of donanemab, monoclonal antibody that target Aβ plaques, fibrils, soluble protofibrils, and oligomeric Aβ species all targeting A β plaques, required p eople with early AD to have both positive amyloid PET and tau-PET, further dividing participants into low and intermediate/high positive tau burden groups.(464)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [464]
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“The first therapies for AD targeting the removal of amyloid are now being approved with modest positive outcomes, although associated with several side effects (Sims et al. 2023; Mintun et al. 2021; Van Dyck et al. 2023).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“One response to these problems has been the design of clinical instruments that purport to be able to reveal treatment effects with greater sensitivity: for example, the iADRS 83 or the preclinical Alzheimer cognitive composite 96 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [83]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citationMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Cited by
Items 201–300 of 1,008
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers
Janelidze, S., Christian, B. T., Price, J., Laymon, C., Schupf, N., Klunk, W. E., Lott, I., Silverman, W., Rosas, H. D., Zaman, S., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1740 · Cited by 60
Tau‐PET is superior to phospho‐tau when predicting cognitive decline in symptomatic AD patients
Smith, R., Cullen, N. C., Pichet Binette, A., Leuzy, A., Blennow, K., Zetterberg, H., Klein, G., Borroni, E., Ossenkoppele, R., Janelidze, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12875 · Cited by 60
Dickson, S. P., Wessels, A. M., Dowsett, S. A., Mallinckrodt, C., Sparks, J. D., Chatterjee, S., & Hendrix, S. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.50 · Cited by 58
“For example, a small difference in absolute point change between DMT and placebo groups on a scale with a large range may be viewed as a JPAD - Volume 10, Number 3, 2023 Footnote: For a) to c), Part I shows mean +/- standard error; Part II shows mean and 95% con dence interval; Abbreviations: CDR-SB, Clinical Dementia…”
BackgroundMethodInfluentialSelf-citationLoss of insulin signaling in astrocytes exacerbates Alzheimer-like phenotypes in a 5xFAD mouse model
Chen, W., Huang, Q., Lazdon, E., Gomes, A., Wong, M., Stephens, E. R., Royal, T. G., Frenkel, D., Cai, W., & Kahn, C. R. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220684120 · Cited by 79
Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer’s disease
Liu, K. Y., Villain, N., Ayton, S., Ackley, S. F., Planche, V., Howard, R., & Thambisetty, M. (2023) · Brain Communications · doi:10.1093/braincomms/fcad175 · Cited by 58
Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development
Cummings, J. L., Osse, A. M. L., Kinney, J. W., Cammann, D., & Chen, J. (2024) · CNS Drugs · doi:10.1007/s40263-024-01103-1 · Cited by 75
“In its Phase 2 and Phase 3 trials, donanemab was discontinued when Aβ plaque levels were reduced to below detectable limits [33, 34].”
Cummings, J. L., & Kinney, J. W. (2022) · Medicina · doi:10.3390/medicina58070952 · Cited by 64
Fluid biomarkers in Alzheimer's disease
Simrén, J., Elmgren, A., Blennow, K., & Zetterberg, H. (2023) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2022.09.006 · Cited by 58
Barbera, M., Lehtisalo, J., Perera, D., Aspö, M., Cross, M., de Jager, C. A., Falaschetti, E., Friel, N., Luchsinger, J. A., Gavelin, H. M., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01355-x · Cited by 66
“Despite recent promising findings from anti-amyloid monoclonal antibodies, [2–4] the failure of many single-intervention pharmacological and non-pharmacological trials in AD highlights an urgent need for new multimodal therapy approaches targeting simultaneously several disease mechanisms and…”
BackgroundMechanistic insights and emerging therapeutic stratagems for Alzheimer’s disease
Rajendran, K., & Krishnan, U. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102309 · Cited by 63
Indole-Based Compounds in the Development of Anti-Neurodegenerative Agents
Barresi, E., Baglini, E., Poggetti, V., Castagnoli, J., Giorgini, D., Salerno, S., Taliani, S., & Settimo, F. D. (2024) · Molecules · doi:10.3390/molecules29092127 · Cited by 63
Söderberg, L., Johannesson, M., Gkanatsiou, E., Nygren, P., Fritz, N., Zachrisson, O., Rachalski, A., Svensson, A.-S., Button, E. B., Dentoni, G., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61691-2 · Cited by 71
“Although a relatively high ARIA-E frequency of 24% has been reported for donanemab 16,35 , we found that it showed variable binding to CAA Aβ fibrils from different individuals, with a preference for fibrils containing higher levels of AβpE3-40.”
Liao, J., He, W., Li, L., Wang, J., Gong, L., Zhang, Q., & Lin, Z. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2025.100016 · Cited by 77
Ahmed, H., Wang, Y., Griffiths, W. J., Levey, A. I., Pikuleva, I., Liang, S. H., & Haider, A. (2024) · Brain · doi:10.1093/brain/awae028 · Cited by 56
Recent advancement in therapeutic strategies for Alzheimer’s disease: Insights from clinical trials
Khan, T., Waseem, R., Shahid, M., Ansari, J., Ahanger, I. A., Hassan, M. I., & Islam, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102113 · Cited by 62
The Efficacy and Safety of Alzheimer’s Disease Therapies: An Updated Umbrella Review
Fan, F., Liu, H., Shi, X., Ai, Y., Liu, Q., & Cheng, Y. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215423 · Cited by 64
Clinical considerations in early-onset cerebral amyloid angiopathy
Banerjee, G., Collinge, J., Fox, N. C., Lashley, T., Mead, S., Schott, J. M., Werring, D. J., & Ryan, N. S. (2023) · Brain · doi:10.1093/brain/awad193 · Cited by 61
Mundada, N. S., Rojas, J. C., VandeVrede, L. A., Thijssen, E. H., Iaccarino, L., Okoye, O., Shankar, R. P., Soleimani‐Meigooni, D. N., Lago, A. L., Miller, B. L., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01302-w · Cited by 59
“We aimed to further characterize the relationship between tau-PET and plasma p-tau by focusing on these markers in amyloid-PET-positive patients at the early clinical stages of AD—similar to patients included in multiple clinical trials [15, 16].”
Promoting Alzheimer’s disease research and therapy with stem cell technology
Cao, Z., Kong, F., Ding, J., Chen, C., He, F., & Deng, W. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03737-w · Cited by 66
“Currently, Aβ and tau pathologies remain the focus of new therapies undergoing clinical trials for AD, which include monoclonal antibodies targeting Aβ[50, 88, 109, 131], the β-secretase (BACE1) inhibitor that inhibits secretase activity to lessen Aβ deposition [35], and drugs that target tau protein [94].”
BackgroundInsights into the use of biomarkers in clinical trials in Alzheimer's disease
Pascoal, T. A., Aguzzoli, C. S., Lussier, F. Z., Crivelli, L., Suemoto, C. K., Fortea, J., Rosa‐Neto, P., Zimmer, E. R., Ferreira, P. C. L., & Bellaver, B. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105322 · Cited by 68
“46, 47”
Drug delivery strategies with lipid-based nanoparticles for Alzheimer’s disease treatment
Jang, Y.-J., Kang, S.-J., Park, H. S., Lee, D., Kim, J. H., Kim, J.-E., Kim, D., Chung, C., Yoon, J., & Bhang, S. H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03109-3 · Cited by 72
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions
Rafii, M. S., & Aisen, P. S. S. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01123-5 · Cited by 73
Symptomatic, Genetic, and Mechanistic Overlaps between Autism and Alzheimer’s Disease
Nadeem, M. S., Hosawi, S. B. I., Alshehri, S., Ghoneim, M. M., Imam, S. S., Murtaza, B. N., & Kazmi, I. A. (2021) · Biomolecules · doi:10.3390/biom11111635 · Cited by 63
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecìć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 56
“, 2021b), and approximately 30–35% slowing in the phase 2 donanemab study (Mintun et al., 2021).”
BackgroundInfluentialThe Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes
Kepp, K. P., Sensi, S. L., Johnsen, K. B., Barrio, J. R., Høilund-Carlsen, P. F., Neve, R. L., Alavi, A., Herrup, K., Perry, G., Robakis, N. K., et al. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-230099 · Cited by 53
Schindler, S. E., & Atri, A. (2023) · Nature Aging · doi:10.1038/s43587-023-00400-6 · Cited by 49
Quantification of amyloid beta and tau PET without a structural MRI
Landau, S. M., Ward, T. J., Murphy, A., Iaccarino, L., Harrison, T. M., La Joie, R., Baker, S., Koeppe, R. A., Jagust, W. J., & Initiative, F. T. A. D. N. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12668 · Cited by 50
Cognitive impairment and World Trade Centre-related exposures
Clouston, S., Hall, C. B., Kritikos, M., Bennett, D. A., DeKosky, S. T., Edwards, J. D., Finch, C. E., Kreisl, W. C., Mielke, M. M., Peskind, E. R., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00576-8 · Cited by 56
Groot, C., Smith, R., Stomrud, E., Binette, A. P., Leuzy, A., Wuestefeld, A., Wisse, L. E. M., Palmqvist, S., Mattsson-Carlgren, N., Janelidze, S., et al. (2023) · Brain · doi:10.1093/brain/awac329 · Cited by 50
“We also did not account for the possible confounding effects of co-pathologies such as vascular injury and TDP-43 deposition on longitudinal tau, atrophy and cognition between groups.”
Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease
Spotorno, N., Strandberg, O. T., Vis, G., Stomrud, E., Nilsson, M., & Hansson, O. (2022) · Brain · doi:10.1093/brain/awac343 · Cited by 56
“4–7 However, the results from such trials have been puzzling.”
Aranda, M., Márquez, D. X., Gallagher-Thompson, D. E., Pérez, A., Rojas, J. C., Hill, C. V., Reyes, Y., Dilworth‐Anderson, P., & Portacolone, E. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12389 · Cited by 63
Passive Alzheimer’s immunotherapy: A promising or uncertain option?
Høilund‐Carlsen, P. F., Revheim, M.-E. R., Costa, T., Alavi, A. A., Kepp, K. P., Sensi, S. L., Perry, G. L., Robakis, N. K. R. K., Barrio, J. R., & Vissel, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101996 · Cited by 56
Systemic determinants of brain health in ageing
Smith, E. E., Biessels, G. J., Gao, V., Gottesman, R. F., Liesz, A., Parikh, N. S., & Iadecola, C. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01016-z · Cited by 60
“Recent phase III trials of anti-Aβ monoclonal antibodies for the treatment of Alzheimer disease, shown to be highly effective at removing plaque amyloid, reduced the rate of cognitive decline but only by 22–27% 6,7 .”
Diagnosis and Treatment of Alzheimer’s Disease:
Bomasang-Layno, E., & Bronsther, R. (2021) · Delaware Journal of Public Health · doi:10.32481/djph.2021.09.009 · Cited by 76
McDade, E. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001131 · Cited by 64
Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine
Iannone, L. F., Cesaris, F. D., Ferrari, A., Benemei, S., Fattori, D., & Chiarugi, A. (2022) · Cephalalgia · doi:10.1177/03331024221111526 · Cited by 54
“Further, clinical evidence that subcutaneously-injected anti-amyloid mAbs such as aducanumab (22), lecanemab (23), donanemab (24) and ganterenumab (25) cross the BBB and strongly reduce the brain amyloid load in patients demonstrates that peripherally-administered mAbs can exert a pharmacodynamic effects within the br…”
BackgroundHajjo, R., Sabbah, D. A., Abusara, O. H., & Bawab, A. Q. A. (2022) · Diagnostics · doi:10.3390/diagnostics12122975 · Cited by 63
Hussain, S. M., Robb, C. E., Tonkin, A. M., Lacaze, P. A., Chong, T. T. ‐., Beilin, L. J., Yu, C., Watts, G. F., Ryan, J. L., Ernst, M. E., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100963 · Cited by 69
“24”
Huang, Z., Hamblin, M. R., & Zhang, Q. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01484-x · Cited by 57
“…the treatment duration was relatively short compared to current clinical trials on AD therapeutic intervention, typically lasting 18 months [175, 176], this preliminary trial is encouraging as it suggests that a relatively short treatment period for this therapy may be sufficient to produce…”
Donanemab in Early Alzheimer’s Disease
(2021) · New England Journal of Medicine · doi:10.1056/nejmc2109455 · Cited by 50
Self-citationTherapeutic potential of glutaminyl cyclases: Current status and emerging trends
Coimbra, J. R. M., Moreira, P. I., Santos, A. E., & Salvador, J. A. R. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103644 · Cited by 56
Bollack, A., Pemberton, H., Collij, L. E., Markiewicz, P. J., Cash, D. M., Farrar, G., & Barkhof, F. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13158 · Cited by 53
“10,23,24 In summary, the review highlights that current studies primarily use publicly available data sets to assess change in amyloid over 2 years with static acquisitions.”
BackgroundMethodZhao, Z., Liu, Y., Ruan, S., & Hu, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s444115 · Cited by 49
Bioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities
Li, S., & Stern, A. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01589-5 · Cited by 51
“Anti-Aβ antibodies Early attempts at targeting Aβ with monoclonal antibodies failed to alleviate cognitive decline compared to placebo, though more recent trials have evinced mixed success [17, 18].”
BackgroundResultJoseph‐Mathurin, N., Llibre‐Guerra, J. J., Li, Y., McCullough, A. A., Hofmann, C., Wojtowicz, J., Park, E., Wang, G., Preboske, G. M., Wang, Q., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26511 · Cited by 47
Self-citationHuang, P., Zhang, L., Tan, Y., & Chen, S. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00337-1 · Cited by 63
Kršek, A., & Batičić, L. (2024) · Future Pharmacology · doi:10.3390/futurepharmacol4020020 · Cited by 63
“Long-term extension trials at different phases of Alzheimer’s disease are ongoing [94].”
BackgroundBiomarkers of Alzheimer’s disease: Past, present and future clinical use
Georgakas, J. E., Howe, M. D., Thompson, L. I., Riera, N. M., & Riddle, M. C. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100063 · Cited by 58
Choroid Plexus Volume, Amyloid Burden, and Cognition in the Alzheimer’s Disease Continuum
Jeong, S. H., Park, C. J., Cha, J., Kim, S.-Y., Lee, S., Kim, Y. J., Sohn, Y. H., Chung, S. J., & Lee, P. H. (2024) · Aging and Disease · doi:10.14336/ad.2024.0118 · Cited by 85
Fleisher, A., Munsie, L. M., David, P., Andersen, S. W., Higgins, I. A., Hauck, P. M., Lo, A., Sims, J. R., Bryś, M., Mintun, M. A., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000208061 · Cited by 57
Self-citationClinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease
Barba, L., Abu‐Rumeileh, S., Barthel, H., Massa, F., Foschi, M., Bellomo, G., Gaetani, L., Thal, D. R., Parnetti, L., & Otto, M. (2024) · Brain · doi:10.1093/brain/awae203 · Cited by 62
Treatment of Alzheimer Disease
Geldmacher, D. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001503 · Cited by 53
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials
Weiner, M. W., Kanoria, S., Miller, M. J., Aisen, P. S. S., Beckett, L. A., Conti, C., Diaz, A., Flenniken, D., Green, R. C., Harvey, D. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14321 · Cited by 65
Wang, Y., Liu, S., Spiteri, A. G., Huynh, A. L. H., Chu, C., Masters, C. L., Goudey, B., Pan, Y., & Jin, L. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01540-6 · Cited by 61
“The development of anti-Aβ monoclonal antibodies, such as donanemab [40] and lecanemab [41], has shown promising results in reducing cognitive decline in early treatment scenarios.”
BackgroundClarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease
Chen, C., Katayama, S., Lee, J. H., Lee, J.-Y., Nakagawa, M., Torii, K., Ogawa, T., Dash, A., Irizarry, M. C., Dhadda, S., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100160 · Cited by 60
Soluble Amyloid-β Consumption in Alzheimer’s Disease
Espay, A. J., Sturchio, A., Schneider, L. S., & Ezzat, K. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-210415 · Cited by 45
Malpetti, M., Joie, R. L., & Rabinovici, G. D. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263694 · Cited by 45
“In a recent phase 2 trial of donanemab (37), a monoclonal antibody targeting the pyroglutamate epitope on Ab plaques, (18)F-flortaucipir PET was used to limit trial inclusion to patients with intermediate tau deposition.”
MethodJovalekic, A., Roé-Vellvé, N., Koglin, N., Lagos‐Quintana, M., Nelson, A. S., Diemling, M., Lilja, J., Gómez-González, J. P., Doré, V., Bourgeat, P., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06279-0 · Cited by 49
Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
Veverová, K., Laczó, J., Katonová, A., Horáková, H., Matušková, V., Angelucci, F., Laczó, M., Nedelská, Z., Hort, J., Wang, H., et al. (2024) · Autophagy · doi:10.1080/15548627.2024.2340408 · Cited by 50
“While it is exciting that these drugs reduced the rate of AD-associated memory loss by approximately 35% during phase 3 clinical trials, it is unfortunate that drugs or strategies that cure AD-associated cognitive decline have not yet been discovered [3,4].”
BackgroundConsiderations for widespread implementation of blood‐based biomarkers of Alzheimer's disease
Mielke, M. M., Anderson, M., Ashford, J. W., Jeromin, A., Lin, P., Rosen, A. C., Tyrone, J., VandeVrede, L. A., Willis, D. R., Hansson, O., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14150 · Cited by 50
“14,15 While BBM tests have been widely used in AD research studies and clinical trials, 10,12,13,16 several important considerations must be addressed for their widespread implementation in clinical practice.”
Young, C. B., Landau, S. M., Harrison, T. M., Poston, K. L., & Mormino, E. C. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118553 · Cited by 45
Volloch, V., & Rits‐Volloch, S. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230164 · Cited by 50
“Conceptually similar, both quantitatively and qualitatively, results in clinical trials for treatment of very early symptomatic AD were recently obtained with donanemab, a humanized IgG1 antibody directed at an N-terminal pyroglutamate A epitope that is present only in established plaques [20, 21].”
ResultImplications of the Approval of Lecanemab for Alzheimer Disease Patient Care
Knopman, D. S., & Hershey, L. A. (2023) · Neurology · doi:10.1212/wnl.0000000000207438 · Cited by 51
“Knowledge of APOE genotype was highly relevant to the risk of ARIA because carriage of 1 e4 allele approximately doubles the risk of ARIA from lecanemab(36) and donanemab.(27) Risks are nearly 4 times higher for APOE e4 homozygotes compared with noncarriers.”
BackgroundSima, D. M., Phan, T. V., Eyndhoven, S. V., Vercruyssen, S., Magalhães, R. J. D. S., Liseune, A., Brys, A., Frenyo, P., Terzopoulos, V., Maes, C., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.55800 · Cited by 48
Dobson, R., Patterson, K., Malik, R., Mandal, U., Asif, H., Humphreys, R. A., Payne, M., O-charoenrat, E., Huzzey, L., Clare, A., et al. (2024) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-333468 · Cited by 53
Planche, V., & Villain, N. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3126 · Cited by 43
“of AD, the application of these operational criteria to establish amyloid-load measured with PET as a surrogate endpoint would require that: (1) the treatment has an effect on cognitive decline; (2) the treatment effect on slowing cognitive decline is captured by amyloid load; (3) the treatment has an effect on amyloi…”
MethodLiu, W., Li, Y., Zhao, T., Gong, M., Wang, X., Zhang, Y., Xu, L., Li, W., Li, Y., & Jia, J. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102534 · Cited by 46
Monoclonal Antibody Therapy in Alzheimer’s Disease
Neațu, M., Covaliu, A., Ioniță, I., Jugurt, A., Davidescu, E. I., & Popescu, B. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010060 · Cited by 48
“This antibody has demonstrated the ability to bind to amyloid plaques, reduce the plaque burden, ameliorate measures of synaptotoxicity, and enhance performance in mouse behavioral assays [102,104].”
BackgroundA Survey on Computational Methods in Drug Discovery for Neurodegenerative Diseases
Vicidomini, C., Fontanella, F., D’Alessandro, T., & Roviello, G. N. (2024) · Biomolecules · doi:10.3390/biom14101330 · Cited by 50
Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis
Almeida, Z. L., Vaz, D. C., & Brito, R. M. M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04543-4 · Cited by 52
“A11 and OC antibodies are known to recognize other amyloid-forming epitopes independently of the amino acid sequence of the protein [202, 203] and are currently being tested as anti-amyloid immunotherapies [204, 205].”
Yamashita, K., Miura, M., Watanabe, S., Ishiki, K., Arimatsu, Y., Kawahira, J., Kubo, T., Sasaki, K., Arai, T., Hagino, K., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01029-0 · Cited by 42
Roles of humanin and derivatives on the pathology of neurodegenerative diseases and cognition
Thiankhaw, K., Chattipakorn, K., Chattipakorn, S. C., & Chattipakorn, N. (2022) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2022.130097 · Cited by 45
Babalola, J. A., Lang, M., George, M., Stracke, A., Tam‐Amersdorfer, C., Itxaso, I., Lucija, D., Tadić, J., Schilcher, I., Loeffler, T., et al. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148518 · Cited by 47
“, 2021; Slomski,2022), and two recently approved anti-amyloid monoclonal antibodies; Aducanumab and Lecanemab are expensive and have associated side effects (Mintun et al., 2021; Swanson et al., 2021; Lacorte et al., 2022; Cummings, 2023).”
Poliakova, T., & Wellington, C. L. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00671-y · Cited by 48
Lantero-Rodriguez, J., Salvadó, G., Snellman, A., Montoliu-Gaya, L., Brum, W. S., Benedet, A. L., Mattsson-Carlgren, N., Tideman, P., Janelidze, S., Palmqvist, S., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00707-x · Cited by 41
A Nanozyme-Boosted MOF-CRISPR Platform for Treatment of Alzheimer’s Disease
Yang, J., Qin, G., Liu, Z., Zhang, H., Du, X., Ren, J., & Qu, X. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c02272 · Cited by 49
Frick, E. A., Emilsson, V., Jónmundsson, Þ., Steindorsdottir, A. E., Johnson, E. C. B., Puerta, R., Dammer, E. B., Shantaraman, A., Cano, A. C., Boada, M., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00693-1 · Cited by 50
“We found differential associations between the strata for several proteins, potentially suggesting that different pathways vary in their contribution to the development of LOAD depending on APOE-ε4 carrier status (Supplementary Note 7 and Supplementary Table 15).”
InfluentialTosun, D., Hausle, Z., Thropp, P., Concha‐Marambio, L., Lamoureux, J., Lebovitz, R., Shaw, L. M. J., Singleton, A., Weiner, M. W., Initiative, T. A. D. N., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14276 · Cited by 51
Concordance Between Amyloid-PET Quantification and Real-World Visual Reads
Zeltzer, E., Schonhaut, D. R., Mundada, N. S., Blazhenets, G., Mejía, J. A., Soleimani‐Meigooni, D. N., Cho, H., Ranasinghe, K. G., Windon, C., Yadollahikhales, G., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2218 · Cited by 49
Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER‐ALZ 3
Yaari, R., Holdridge, K. C., Williamson, M., Wessels, A. M., Shcherbinin, S., Kotari, V., Reiman, E. M., Tariot, P. N., Alexander, R., Langbaum, J. B. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70662 · Cited by 54
“24 As it has been observed previously that global assessment might be inadequate to capture the FTP signal in preclinical AD, investigators characterized regional tau deposition patterns in brain lobes encompassing the entire neocortex and arranged according to hypothetical tau spread using a…”
Self-citationPrados, M. J., Liu, Y., Jun, H., Lam, J., & Mattke, S. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12578 · Cited by 42
Microglia degrade Alzheimer’s amyloid-beta deposits extracellularly via digestive exophagy
Jacquet, R. G., González Ibáñez, F., Picard, K., Funes, L., Khakpour, M., Gouras, G. K., Tremblay, M.-È., Maxfield, F. R., & Solé-Domènech, S. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115052 · Cited by 42
Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies
Loomis, S. J., Miller, R., Castrillo‐Viguera, C., Umans, K., Cheng, W., O'Gorman, J. T., Hughes, R. A., Haeberlein, S. B., & Whelan, C. D. (2023) · Neurology · doi:10.1212/wnl.0000000000207919 · Cited by 45
Bollack, A., Collij, L. E., García, D. V., Shekari, M., Altomare, D., Payoux, P., Dubois, B., Grau‐Rivera, O., Boada, M., Marquié, M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13761 · Cited by 50
“3,4,15 The CL approach was introduced in 2015 as a means of calibrating measures of A β deposits to a tracer-independent unbounded scale, where 0 (value characteristic of young healthy controls) and 100 (typical AD subjects) act as anchor points.”
Sarazin, M., Lagarde, J., Haddad, I., de Souza, L. C., Bellier, B., Potier, M., Bottlaender, M., & Dorothée, G. (2024) · Nature Aging · doi:10.1038/s43587-024-00630-2 · Cited by 46
“Nevertheless, selecting patients based on a high regional tau load seems contradictory to the goal of targeting the earliest stage of AD, as defined in the trial with donanemab, in which patients considered to have the highest tau levels were excluded 64 .”
Munir, M. U., Ali, S. A., Chung, K. H. K., Käkinen, A., Javed, I., & Davis, T. P. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2422468 · Cited by 46
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Nimmo, J., Kelly, L., Verma, A. K., Carare, R. O., Nicoll, J. A. R., & Dodart, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.733857 · Cited by 45
APOE Antibody Inhibits Aβ‐Associated Tau Seeding and Spreading in a Mouse Model
Gratuze, M., Jiang, H., Wang, C., Xiong, M., Bao, X., & Holtzman, D. M. (2022) · Annals of Neurology · doi:10.1002/ana.26351 · Cited by 41
Liu, X., Wang, X., Shi, L., Liu, Y., Wang, L., Li, K., Bu, Q., Cen, X., & Yu, X. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01046 · Cited by 42
Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates
Wessels, A. M., Rentz, D. M., Case, M., Lauzon, S., & Sims, J. R. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12312 · Cited by 40
Self-citationTau positron emission tomography in preclinical Alzheimer’s disease
Insel, P. S., Young, C. B., Aisen, P. S. S., Johnson, K. A., Sperling, R. A., Mormino, E. C., & Donohue, M. (2022) · Brain · doi:10.1093/brain/awac299 · Cited by 43
Progress with Treatments for Alzheimer’s Disease
Levey, A. I. (2021) · New England Journal of Medicine · doi:10.1056/nejme2103722 · Cited by 41
Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Levin, J., Vöglein, J., Quiroz, Y. T., Bateman, R. J., Ghisays, V., Lopera, F., McDade, E., Reiman, E., Tariot, P. N., & Morris, J. C. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12624 · Cited by 40
Causal links among amyloid, tau, and neurodegeneration
Bilgel, M., Wong, D. F., Moghekar, A. R., Ferrucci, L., Resnick, S. M., & Initiative, T. A. D. N. (2022) · Brain Communications · doi:10.1093/braincomms/fcac193 · Cited by 40
“47 An amyloid intervention earlier in the disease course, combined with a tau-targeting therapy, might yield more pronounced effects on neocortical tau.”
Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing
Marques, C. F., Marques, M. M., & Justino, G. C. (2022) · Pharmaceuticals · doi:10.3390/ph15091039 · Cited by 55
Tarawneh, R. M., & Pankratz, V. S. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01412-z · Cited by 51
“Emerging data from other AD trials suggests that clinical outcomes of anti-amyloid therapies in early symptomatic AD may be influenced by differences in baseline burden of tau pathology [9, 31, 45].”
BackgroundBACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives
Coimbra, J. R. M., Resende, R., Custódio, J. B. A., Salvador, J. A. R., & Santos, A. E. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240146 · Cited by 51
Bougea, A. M., & Gourzis, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164661 · Cited by 47
Adenosine receptor signalling in Alzheimer’s disease
Trinh, P. N. H., Baltos, J., Hellyer, S. D., May, L. T., & Gregory, K. J. (2022) · Purinergic Signalling · doi:10.1007/s11302-022-09883-1 · Cited by 44
Vascular risk burden is a key player in the early progression of Alzheimer’s disease
Ferrari‐Souza, J. P., Brum, W. S., Hauschild, L. A., Ros, L. U. D., Ferreira, P. C. L., Bellaver, B., Leffa, D. T., Bieger, A., Tissot, C., Lussier, F. Z., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.12.008 · Cited by 43
Metadata
- Authors
- Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., Apostolova, L. G., Salloway, S. P., & Skovronsky, D. M.
- Affiliations
- Eli Lilly (United States) (US)
- From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) — both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).
- Brown University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-06
- Volume
- 384
- Issue
- 18
- Pages
- 1691-1704
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3137826907
- Cited by
- 1,728
- References
- 39
- Citations by year
- 2026: 302 · 2025: 409 · 2024: 369 · 2023: 271 · 2022: 263 · 2021: 112
- FWCI
- 160.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- donanemab, early Alzheimer's disease, amyloid-beta, anti-amyloid antibodies, amyloid plaques, tau burden, activities of daily living, cognitive decline
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Alzheimer Disease, Epitopes, Brain Edema, Cognition, Double-Blind Method, Female, Humans, Male, Pyrrolidonecarboxylic Acid, Severity of Illness Index, Disease Progression, Plaque, Amyloid, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.